drugset / Trial / NCT01264211

Safety and Efficacy of the Combination of Diacerein 100 mg Daily and MTX Versus MTX Alone in the Treatment of Early Rheumatoid Arthritis (RA)

NCT01264211

Phase 2 Completed 40 enrolled TRB Chemedica
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the efficacy of Diacerein 100 mg daily versus placebo in reducing rheumatoid arthritis symptoms, when added to stable oral MTX therapy in patients with active early RA. To evaluate the safety of Diacerein 100 mg daily when administrated in combination with oral MTX therapy in those patients for up to 24 weeks To investigate a potential persistent effect, 4 weeks after Diacerein treatment is stopped (carry-over effect)

Timeline

Start
2010-10
Primary completion
2012-06
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Diacerein Small molecule 100 mg

Indications